Vemurafenib: Pharmacologic Profile, Clinical Applications, and Management in Primary Care and Family Medicine

Background: Mutations within the mitogen-activated protein kinase (MAPK) pathway—particularly BRAF V600 mutations—play a central role in the pathogenesis of malignant melanoma and other malignancies. These mutations drive uncontrolled cellular proliferation and tumor progression. Vemurafenib, a selective BRAF inhibitor, represents a landmark advancement in targeted oncologic therapy.  Aim: This review aims to summarize the pharmacologic profile, clinical indications, safety considerations, and monitoring requirements of vemurafenib, with emphasis on its relevance to primary care and family medicine practice.  Methods: A narrative review was conducted using data from pivotal clinical trials, FDA approvals, and clinical guideline recommendations addressing vemurafenib’s efficacy, pharmacokinetics, adverse effects, contraindications, and monitoring strategies.  Results: Vemurafenib demonstrated significant improvements in overall and progression-free survival in patients with BRAF V600E–mutated metastatic melanoma compared with dacarbazine. Common adverse effects include dermatologic toxicity, photosensitivity, QT prolongation, hepatotoxicity, nephrotoxicity, and secondary cutaneous malignancies. Resistance mechanisms frequently develop, supporting the use of combination therapy with MEK inhibitors.  Conclusion: Vemurafenib remains a critical component of precision oncology for BRAF V600–mutant malignancies. Safe and effective use requires careful patient selection, interdisciplinary collaboration, proactive monitoring, and patient education to optimize outcomes and minimize toxicity.